Annolyse
BriefingsCompaniesInsightsPrinciplesCompareWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology
  • Developers

© 2026 Annolyse. Analytical briefings for NZX company announcements.

Table of contents

  1. What changed
  2. What matters
  3. Expectations
  4. Quality of result
  5. Unresolved
  6. Key metrics
  7. Segment breakdown
  8. Analytical metrics
  9. Metric context
  10. Reference material
←Back to briefings
Ryman Healthcare (RYM) / FY25

Revenue up 10.3% but FY25 NPAT loss deepens to $436.8m as H2 swings sharply

Equity-raise proceeds cut gross debt by $860.5m, yet a 102.8% effective tax rate and a $531.2m implied H2 NPAT swing dominate the result.

Release date
29 May 2025
Published
28 April 2026
Table of Contents⌄
  1. What changed
  2. What matters
  3. Expectations
  4. Quality of result
  5. Unresolved
  6. Key metrics
  7. Segment breakdown
  8. Analytical metrics
  9. Metric context
  10. Reference material

What changed

Revenue rose 10.3% to $760.7m, but every profit and cash measure went the other way. PBT loss widened to -$215.4m from -$144.9m (-48.6%), and reported NPAT fell to -$436.8m from $4.8m on the comparable disclosure (the FY24 figure was subsequently restated to -$169.7m in the current release). Operating cash flow dropped 37.7% to $410.3m, and the company's own free cash flow measure was -$94.2m, which it described as in line with the equity-raise outlook. Gross borrowings were cut by $860.5m to $1.7b, and net debt improved to $1.7b from $2.5b. No dividend was declared. Cash on hand fell to $17.7m from $41.8m. EBITDAF, the company-defined earnings measure, rose to $45.5m from $14.8m.

What matters

  • Tax line, not operating leverage, drives the NPAT gap. A $221.4m tax expense on a $215.4m PBT loss produces a 102.8% effective rate, versus a tax credit in the prior year. PBT growth of -48.6% is the cleaner read on the operating swing; the further leg from PBT to NPAT is tax-driven, not a discontinued operation.
  • Fair-value movements dominate the H2 shape. HY25 NPAT was a positive $94.4m, so the full-year -$436.8m implies an H2 NPAT of -$531.2m. For a retirement-village operator, that profile is consistent with a large second-half investment-property fair-value write-down rather than an operating collapse, and the release's reference to PBTF and EBITDAF non-GAAP measures points the same way.
  • Balance-sheet direction has reversed. Gross borrowings fell 33.8% and net debt by roughly $836m, materially reducing leverage even as equity eased 3.5% to $4.3b. This is the clearest positive read in the release and reflects the announced equity raise being deployed against debt.

Expectations

No numerical FY25 guidance, medium-term revenue target, or forward-sales backlog metric was supplied, so the result cannot be benchmarked to a stated plan. Management framed the -$94.2m company-defined free cash flow as consistent with the equity-raise outlook, and flagged improving sales-contract momentum into Q4 with total ORA sales of 1,523 versus 1,574 in FY24. EBITDAF tripling off a low base and revenue growth of 10.3% are supportive operating signals, but the release does not provide enough shape context to judge whether the H2 fair-value impact is a one-off reset or a continuing trajectory.

Quality of result

Earnings quality is mixed. The 10.3% revenue lift and EBITDAF improvement to $45.5m look operating in nature, and debt reduction is real cash applied from the equity raise. Against that, operating cash flow fell $248.2m year on year, and HY25 already accounted for 68.9% of full-year operating cash flow, implying a sharply weaker H2 cash contribution of $127.5m. Working capital absorbed cash, with trade receivables rising from effectively nil to $22.1m and operating working capital up $22.1m. Cash conversion deteriorated materially against both the prior year and the H1 run-rate. The headline NPAT loss is heavily influenced by fair-value movements and a punitive tax outcome rather than a clean operating read, so the underlying durability of the result rests on EBITDAF and sales-momentum claims that the supplied excerpts do not fully reconcile.

Unresolved

  • What is the size and composition of the H2 fair-value charge that took NPAT from +$94.4m at the half to -$436.8m for the year?
  • Why is the FY24 NPAT comparable now stated as -$169.7m versus the originally reported $4.8m, and what was restated?
  • What drives the 102.8% effective tax rate, and is any portion of the $221.4m tax expense non-cash deferred tax that could reverse?
  • What is the company's reconciliation between cash-flow-statement OCF less capex of $306.4m and the disclosed -$94.2m free cash flow figure?
  • With dividends suspended, what is the capital-return framework once development cash outflows normalise?

This briefing cannot assess underlying village-level cash-resale dynamics, occupancy, or the embedded value of the deferred management fee book, none of which are quantified in the supplied material.

Key metrics

← Swipe to view more
Key metrics table for Ryman Healthcare FY25
Metric FY25 FY24 Change
Revenue $760.7m $689.9m +10.3% ↑
Net profit after tax −$436.8m $4.8m -9248.3% ↓
Net cash inflow from operating activities $410.3m $658.5m -37.7% ↓
Declared dividend per share 0.0c — —
Profit before tax −$215.4m −$144.9m -48.6% ↓
Cash and cash equivalents $17.7m $41.8m -57.8% ↓
Total assets $12.1b $13.1b -7.8% ↓

Segment breakdown

← Swipe to view more
Segment breakdown table for Ryman Healthcare FY25
Segment Current revenue Prior revenue Current result Mix shift
New Zealand — $556.5m — n/a
Australia — $132.8m — n/a
Other — $0.59m — n/a

Analytical metrics

← Swipe to view more
Analytical metrics table for Ryman Healthcare FY25
Metric FY25 FY24 Context
FCF pre-lease $306.4m $558.8m −$252.4m
FCF post-lease −$94.2m — —
FCF / NPAT 21.6% — complementary conversion metric
Capex % revenue 13.7% 14.5% —
Capex $103.9m $99.7m +$4.2m
Debtor days 10.6 0.0 +10.6 days
Inventory days 1.1 1.3 -0.1 days
Operating working capital $24.5m $2.4m +$22.1m absorbed
Trade debtors $22.1m $0.01m +$22.1m
Net debt $1.7b $2.5b −$836.4m
Gross borrowings $1.7b $2.5b −$860.5m
Payout ratio vs FCF pre-lease 0.0% — covered
ROE (annualised) -10.3% 0.1% Weakening
HY25 share of FY25 revenue 48.1% — Other half was 51.9%
HY25 share of FY25 NPAT -21.6% — Other half was 121.6%
Profit from continuing operations −$436.8m — —

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Source-backed analysis from the filing set attached to this briefing.

Metric context

Trajectory before this result

A compact view of the company's recent revenue and margin path, derived from the same metrics history that powers the company page.

RYM revenue trajectory

Revenue context before the current result.

← Swipe to view more
RYM revenue trajectory preview table
PeriodRYM
HY26$413.8m
FY25$760.7m
HY25$366.3m
HY24$323m
HY23$274.2m

RYM EBITDA margin

Earnings margin across covered periods.

← Swipe to view more
RYM EBITDA margin preview table
PeriodRYM
HY269.7%
FY25n/a
HY25n/a
HY2445.3%
HY23n/a

Appendix

Reference material

Company materials considered in this briefing.

Current period

Ryman Healthcare Limited - Announcement Numbers - 31 March 2025

FY25 / results release↗

Ryman Healthcare Limited - Consolidated Financial Statements - 31 March 2025

FY25 / financial report↗

Prior comparable period

FY24 Result Press Release_FINAL

FY24 / results announcement↗

FY24 Result Press Release_FINAL

FY24 / results release↗

Ryman Healthcare Limited – Financial Statements – 31 March 2024 (including Deloitte Audit Report)

FY24 / financial report↗

Interim context

Ryman Healthcare Limited - Consolidated Interim Financial Statements - 30 September 2024

HY25 / financial report↗

Ryman Healthcare Limited - Media Release - 30 September 2024

HY25 / media release↗

Related insight

See how earnings quality compares across covered companies

→

Email updates

Want briefings like this for the next reporting season?

Get the next Annolyse briefing by email when it is published.

RYM revenue trajectory

Revenue context before the current result.

RYM EBITDA margin

Earnings margin across covered periods.